Drug Trial Radar · NCT07897799
The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Dec 30, 2027
Primary completion
Dec 20, 2029
Study completion Dec 20, 2030
Sponsor
- Lead sponsor
- T-MAXIMUM Pharmaceutical IncIndustry
- Sponsor type
- Industry
- First posted
- Oct 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label, multicenter, single arm Phase II trial to evaluate the safety, tolerability, intracranial efficacy, pharmacokinetics, and pharmacodynamics of MT027 administered ICV in patients with B7-H3-positive brain metastases from advanced solid tumors. The trial consists of two sequential stages: a safety run-in stage followed by a dose expansion stage. Approximately 40 participants are planned for enrollment, including approximately 3 to 6 participants in the safety run in stage and 34 participants in the dose expansion stage. The final number of participants enrolled may vary depending on the safety findings observed during the safety run-in stage. Approximately 3 to 6 eligible participants from the primary target population will receive MT027 3×107 CAR+ T cells via ICV injection on Days 1 and 15 of each 28-day cycle. DLTs will be assessed during a 28-day DLT observation period following the first dose. Following SRC confirmation of acceptable safety during the safety run-in stage, an additional 34 participants will be enrolled to evaluate the intracranial efficacy of MT027 dosed at 3×107 CAR+ T cells.
Conditions
- Brain Metastases From Solid Tumors
Interventions
Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3Biological
MT027 will be injected intracerebroventricularly at a dose of 3×10\^7 cells on Day 1 \& Day 15 of each 28-day treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence rate of Dose-limiting toxicity (DLT)Time frame: up to 28 days
- Intracranial progression-free survival at 6 months (iPFS6)Time frame: up to 6 months
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Delta Hy Research
Houston, Texas
Chang Gung Memorial Hospital, Linkou
Taoyuan, Taoyuan, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.